MA30433B1 - Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires - Google Patents

Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires

Info

Publication number
MA30433B1
MA30433B1 MA31421A MA31421A MA30433B1 MA 30433 B1 MA30433 B1 MA 30433B1 MA 31421 A MA31421 A MA 31421A MA 31421 A MA31421 A MA 31421A MA 30433 B1 MA30433 B1 MA 30433B1
Authority
MA
Morocco
Prior art keywords
pyrazolo
pyrimidine derivatives
respiratory disorders
treating respiratory
disorders
Prior art date
Application number
MA31421A
Other languages
English (en)
Inventor
Ian Bruce
Judy Fox Hayler
Graham Charles Bloomfield
Lee Edwards
Brian Cox
Catherine Howsham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30433(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30433B1 publication Critical patent/MA30433B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU UN SEL OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DANS LAQUELLE R1-R3 ET Y SONT DÉFINIS DANS LA DESCRIPTION, ET SON UTILISATION DANS LE TRAITEMENT DE TROUBLES DANS LESQUELS LA KINASE PI3 EST IMPLIQUÉE.
MA31421A 2006-05-23 2008-11-26 Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires MA30433B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
MA30433B1 true MA30433B1 (fr) 2009-05-04

Family

ID=36687588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31421A MA30433B1 (fr) 2006-05-23 2008-11-26 Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires

Country Status (24)

Country Link
US (5) US20090131457A1 (fr)
EP (1) EP2026811A1 (fr)
JP (1) JP2009537580A (fr)
KR (1) KR101106853B1 (fr)
CN (1) CN101443013A (fr)
AR (2) AR061057A1 (fr)
AU (1) AU2007253615B2 (fr)
BR (1) BRPI0712022A2 (fr)
CA (1) CA2650661A1 (fr)
CL (1) CL2007001455A1 (fr)
CR (1) CR10419A (fr)
EC (1) ECSP088902A (fr)
GB (1) GB0610242D0 (fr)
GT (1) GT200800256A (fr)
IL (1) IL195017A0 (fr)
MA (1) MA30433B1 (fr)
MX (1) MX2008014835A (fr)
NO (1) NO20084997L (fr)
PE (1) PE20080315A1 (fr)
RU (1) RU2008150619A (fr)
TN (1) TNSN08478A1 (fr)
TW (1) TW200806665A (fr)
WO (1) WO2007134828A1 (fr)
ZA (1) ZA200809097B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (fr) 2004-11-19 2007-09-12 The Regents of the University of California Pyrazolopyrimidines anti-inflammatoires
EA200870409A1 (ru) 2006-04-04 2009-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы pi3
AU2008278966B2 (en) * 2007-07-26 2012-02-23 Novartis Ag Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2711558C (fr) 2008-01-04 2016-12-13 Intellikine, Inc. Composes inhibitant la phosphatidyl-inositol-3 kinase
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2111861A1 (fr) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
WO2010006072A2 (fr) 2008-07-08 2010-01-14 The Regents Of The University Of California Modulateurs de mtor et leurs utilisations
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (fr) 2008-10-16 2018-04-03 The Regents Of The University Of California Inhibiteurs d'heteroarylkinase a noyau fusionne
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010114894A1 (fr) 2009-03-31 2010-10-07 Arqule, Inc. Composés hétérocycliques substitués
EP2427195B1 (fr) 2009-05-07 2019-05-01 Intellikine, LLC Composés hétérocycliques et leurs utilisations
JP2013506691A (ja) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
WO2011047384A2 (fr) 2009-10-16 2011-04-21 The Regents Of The University Of California Procédés d'inhibition de l'activité ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011146313A1 (fr) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Composés de pyrazolopyrimidine pour le traitement du cancer
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2751093A1 (fr) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US9150574B2 (en) 2011-09-14 2015-10-06 Proximagen Limited Enzyme inhibitor compounds
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HK1206338A1 (en) 2012-05-22 2016-01-08 北卡罗来纳大学教堂山分校 Pyrimidine compounds for the treatment of cancer
EP2852661A1 (fr) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions et procédés d'obtention et d'utilisation de cellules endodermiques et d'hépatocytes
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
EP2909211A4 (fr) 2012-10-17 2016-06-22 Univ North Carolina Composés pyrazolopyrimidines pour le traitement du cancer
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
WO2014085225A1 (fr) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Composés à base de pyrimidine utilisables à des fins de traitement du cancer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CN106459063A (zh) 2014-04-11 2017-02-22 北卡罗来纳-查佩尔山大学 Mertk‑特异性嘧啶化合物
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
EP3442980B1 (fr) 2016-04-15 2021-06-09 Cancer Research Technology Limited Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase ret
RS63609B1 (sr) 2016-04-15 2022-10-31 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
AR110922A1 (es) * 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN115151550B (zh) * 2019-12-23 2024-11-22 桑福德·伯纳姆·普雷比医学发现研究所 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
AR205234A1 (es) * 1974-05-13 1976-04-12 Lilly Co Eli Procedimiento p a r a preparar compuestos de 3-(5-nitroimidazol-2-il) pirazolo (3,4-d) pirimidina
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
DK2223922T3 (en) * 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
ES2309206T3 (es) * 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
US20030180924A1 (en) 2002-03-22 2003-09-25 Desimone Robert W. Formulation of certain pyrazolo [3,4,-d] pyrimidines as kinase modulators
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2553724A1 (fr) * 2004-02-03 2005-08-18 Abbott Laboratories Utilisation d'aminobenzoxazoles comme agents therapeutiques
EP1831225A2 (fr) * 2004-11-19 2007-09-12 The Regents of the University of California Pyrazolopyrimidines anti-inflammatoires
EP2007373A4 (fr) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc Inhibition de la toxicité de l'alpha-synucléine

Also Published As

Publication number Publication date
ECSP088902A (es) 2008-12-30
AU2007253615B2 (en) 2011-06-23
RU2008150619A (ru) 2010-06-27
EP2026811A1 (fr) 2009-02-25
AR110051A2 (es) 2019-02-20
CR10419A (es) 2011-07-19
MX2008014835A (es) 2008-12-01
AU2007253615A1 (en) 2007-11-29
US20180125849A1 (en) 2018-05-10
TW200806665A (en) 2008-02-01
GB0610242D0 (en) 2006-07-05
IL195017A0 (en) 2009-08-03
BRPI0712022A2 (pt) 2011-12-27
US20140235632A1 (en) 2014-08-21
KR20090008392A (ko) 2009-01-21
US20160303132A1 (en) 2016-10-20
CL2007001455A1 (es) 2008-05-16
KR101106853B1 (ko) 2012-01-19
US20140051698A1 (en) 2014-02-20
CA2650661A1 (fr) 2007-11-29
US8901134B2 (en) 2014-12-02
ZA200809097B (en) 2009-11-25
NO20084997L (no) 2008-12-22
WO2007134828A1 (fr) 2007-11-29
US20090131457A1 (en) 2009-05-21
AR061057A1 (es) 2008-07-30
JP2009537580A (ja) 2009-10-29
TNSN08478A1 (en) 2010-04-14
PE20080315A1 (es) 2008-06-11
CN101443013A (zh) 2009-05-27
GT200800256A (es) 2009-05-28

Similar Documents

Publication Publication Date Title
CA3087089C (fr) Composes cycliques fondus
NO20084997L (no) Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer
WO2008005956A3 (fr) Inhibiteurs de pyrrolotriazine kinase
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
GB0112348D0 (en) Compounds
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
TW200621762A (en) Novel compounds
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
SG172805A1 (en) Amino-heterocyclic compounds used as pde9 inhibitors
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
WO2005063766A3 (fr) Inhibiteurs heterocycliques bicycliques des kinases p-38
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
WO2004009784A3 (fr) Nouveaux inhibiteurs de kinases
NO20091254L (no) Terapeutiske sammensetninger
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister